{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-051513","form_type":"8-K","ticker":"HYPR","cik":"0001833769","company_name":"Hyperfine, Inc.","filed_at":"2023-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.873233+00:00","generated_at":"2026-06-10T05:37:27.196166+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Hyperfine terminates CMO/CSO Khan Siddiqui; transitions to consultant","bullets":["Khan Siddiqui terminated as Chief Medical Officer and Chief Strategy Officer effective September 30, 2023.","Will continue as consultant at $300/hour; salary paid through separation date.","Outstanding equity awards to continue vesting during consulting period under 2021 Equity Plan.","Separation agreement includes $500 payment, standard release, and non-disparagement.","No replacement named for the dual roles."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-051513","json":"https://secwatch.observer/filing/0000950170-23-051513.json","markdown":"https://secwatch.observer/filing/0000950170-23-051513.md","text":"https://secwatch.observer/filing/0000950170-23-051513.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833769/000095017023051513/0000950170-23-051513-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833769/000095017023051513/hypr-20230927.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T05:37:27.196166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c2595c7869","claim":"Khan Siddiqui was terminated as Chief Medical Officer and Chief Strategy Officer at Hyperfine, Inc..","evidence_excerpt":"On September 27, 2023, Hyperfine, Inc. (the “Company”) terminated Khan Siddiqui, M.D.’s part-time employment as the Company’s Chief Medical Officer and Chief Strategy Officer, effective September 30, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833769/000095017023051513/0000950170-23-051513-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Medical Officer and Chief Strategy Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}